United Therapeutics (NASDAQ:UTHR) Given New $600.00 Price Target at HC Wainwright

United Therapeutics (NASDAQ:UTHR) had its price target raised by HC Wainwright from $525.00 to $600.00 in a research note released on Thursday, MarketBeat reports. They currently have a buy rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday. TD Cowen raised their price objective on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group reissued a “buy” rating on shares of United Therapeutics in a report on Tuesday, February 17th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Royal Bank Of Canada lifted their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $533.55.

United Therapeutics Stock Performance

UTHR opened at $503.60 on Thursday. United Therapeutics has a one year low of $266.98 and a one year high of $537.19. The company has a market cap of $21.69 billion, a P/E ratio of 18.05, a PEG ratio of 2.85 and a beta of 0.85. The business’s 50-day simple moving average is $484.64 and its 200-day simple moving average is $444.51.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the company posted $6.19 earnings per share. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $472.13, for a total transaction of $6,817,557.20. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Christopher Causey sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $520.00, for a total value of $520,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at approximately $2,178,800. This trade represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 407,954 shares of company stock worth $197,601,528 over the last three months. 10.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new position in United Therapeutics in the 3rd quarter valued at approximately $317,617,000. Norges Bank acquired a new position in United Therapeutics during the fourth quarter worth $293,418,000. Invesco Ltd. boosted its position in United Therapeutics by 90.2% during the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Finally, Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.